Novo's Wegovy shows improved liver values in post hoc analysis of Essence trial

Novo Nordisk reported that a post hoc analysis of the Phase 3 Essence trial showed Wegovy (semaglutide 2.4 mg) improved liver damage and fibrosis markers versus placebo over 72 weeks. The analysis is exploratory and not a primary endpoint, so regulatory impact is uncertain. This could support broader use of GLP-1 drugs in metabolic liver disease, but confirmatory trials are needed.

AI disclosure: Model-written summary of the source, not a verified fact. Check the sources. How Mosaic works